Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans

US6685949B1 · kind B1 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Xin Gu · San Francisco, US
• John B. Robbins · New York, US

Key dates

• Filing date: Jul 5, 2000
• Grant date: Feb 3, 2004
• Expiry date: Jul 5, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/6037
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A conjugate vaccine for Moraxella (Branhamella) catarrhalis comprising isolated lipooligosaccharide from which esterified fatty acids have been removed, to produce a detoxified lipooligosaccharide (dLOS), or from which lipid A has been removed, to produce a detoxified oligosaccharide (OS), which is linked to an immunogenic carrier. The vaccine is useful for preventing otitis media and respiratory infections caused by M. catarrhalis in mammals, including humans.